Review
doi: 10.1007/s12012-007-0014-4.
Cardiac safety of liposomal anthracyclines
Affiliations
- PMID: 17652807
- DOI: 10.1007/s12012-007-0014-4
Item in Clipboard
Review
Cardiac safety of liposomal anthracyclines
Cardiovasc Toxicol.
2007.
Abstract
Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.
Similar articles
-
Liposomal anthracyclines for breast cancer.Semin Oncol. 2001 Aug;28(4 Suppl 12):32-40. Semin Oncol. 2001. PMID: 11552228 Review.
-
Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?Cancer. 2004 May 15;100(10):2052-63. doi: 10.1002/cncr.20207. Cancer. 2004. PMID: 15139046 Review.
-
Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.Expert Rev Anticancer Ther. 2008 Mar;8(3):331-42. doi: 10.1586/14737140.8.3.331. Expert Rev Anticancer Ther. 2008. PMID: 18366282 Review.
-
[Prevention of cardiotoxic effects of anthracyclines in oncopediatric praxis].Vopr Onkol. 2006;52(5):590-2. Vopr Onkol. 2006. PMID: 17168373 Review. Russian. No abstract available.
-
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).Oncol Rep. 2004 Sep;12(3):549-56. Oncol Rep. 2004. PMID: 15289836 Review.
Cited by
-
Advances of cancer therapy by nanotechnology.Cancer Res Treat. 2009 Mar;41(1):1-11. doi: 10.4143/crt.2009.41.1.1. Epub 2009 Mar 31. Cancer Res Treat. 2009. PMID: 19688065 Free PMC article.
-
A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.Int J Nanomedicine. 2014 Sep 29;9:4581-95. doi: 10.2147/IJN.S69115. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25302024 Free PMC article.
-
Liposomal Formulations in Clinical Use: An Updated Review.Pharmaceutics. 2017 Mar 27;9(2):12. doi: 10.3390/pharmaceutics9020012. Pharmaceutics. 2017. PMID: 28346375 Free PMC article. Review.
-
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.Br J Cancer. 2019 Feb;120(4):379-386. doi: 10.1038/s41416-019-0377-x. Epub 2019 Jan 25. Br J Cancer. 2019. PMID: 30679780 Free PMC article. Clinical Trial.
-
Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.Theranostics. 2014 Aug 24;4(11):1096-111. doi: 10.7150/thno.9423. eCollection 2014. Theranostics. 2014. PMID: 25285163 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
